1. Home
  2. IRWD vs GMRS Comparison

IRWD vs GMRS Comparison

Compare IRWD & GMRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

N/A

Current Price

$3.76

Market Cap

687.4M

Sector

Health Care

ML Signal

N/A

GMRS

GMR Solutions Inc. Class A Common Stock

N/A

Current Price

$9.36

Market Cap

781.0M

ML Signal

N/A

Company Overview

Basic Information
Metric
IRWD
GMRS
Founded
1998
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Transportation Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
687.4M
781.0M
IPO Year
2009
2026

Fundamental Metrics

Financial Performance
Metric
IRWD
GMRS
Price
$3.76
$9.36
Analyst Decision
Buy
Buy
Analyst Count
4
8
Target Price
$6.10
★ $18.88
AVG Volume (30 Days)
★ 1.5M
768.6K
Earning Date
11-09-2026
08-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 1400.00
N/A
EPS
★ 0.55
N/A
Revenue
★ $298,276,000.00
N/A
Revenue This Year
$59.19
$5.13
Revenue Next Year
$4.80
$5.57
P/E Ratio
$7.49
★ N/A
Revenue Growth
★ 8.88
N/A
52 Week Low
$1.41
$9.74
52 Week High
$5.78
$15.98

Technical Indicators

Market Signals
Indicator
IRWD
GMRS
Relative Strength Index (RSI) 40.20 30.08
Support Level $3.89 N/A
Resistance Level $3.96 $14.44
Average True Range (ATR) 0.19 0.67
MACD -0.04 -0.27
Stochastic Oscillator 7.28 5.13

Price Performance

Historical Comparison
IRWD
GMRS

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

About GMRS GMR Solutions Inc. Class A Common Stock

GMR Solutions Inc is a holding company, along with its various subsidiaries, that delivers compassionate, quality medical care, meeting a patient's unplanned and planned care needs. The group provides emergent, non-emergent, disaster response, and event medical services across the healthcare ecosystem, serving local communities, health systems, payors, public health, and local, state, and federal agencies within the United States.

Share on Social Networks: